UCB receives CHMP positive opinion on bringing Neupro back to all patients in Europe
CHMP recommends lifting of treatment restrictions for Neupro in Europe
"The positive opinion of the EMEA's CHMP is an important step towards making Neupro® available to all patients with Parkinson's disease and to patients with Restless Legs Syndrome" said Troy Cox, Senior Vice President CNS Operations, UCB. "UCB is proud of its record of providing innovative treatment solutions for conditions that have a real unmet need. With Neupro® we have a 24 hour, continuous drug delivery treatment that offers patients improvements in their symptoms and benefits to their everyday lives."
In June 2008, Neupro® supply in Europe was limited to patients already established on the drug. UCB has fully implemented a cold-chain storage and distribution system and all stocks of Neupro® (2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h) have been replaced with product that is refrigerated from manufacturer to patient. Pending final approval of the European Commission, Neupro® will be available to all patients with Parkinson's disease in Europe.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.